Abstract
Some chemotherapeutic agents can elicit apoptotic cancer cell death, thereby activating an anticancer immune response that influences therapeutic outcome. We previously reported that anthracyclins are particularly efficient in inducing immunogenic cell death, correlating with the pre-apoptotic exposure of calreticulin (CRT) on the plasma membrane surface of anthracyclin-treated tumor cells. Here, we investigated the role of cellular Ca2+ homeostasis on CRT exposure. A neuroblastoma cell line (SH-SY5Y) failed to expose CRT in response to anthracyclin treatment. This defect in CRT exposure could be overcome by the overexpression of Reticulon-1C, a manipulation that led to a decrease in the Ca2+ concentration within the endoplasmic reticulum lumen. The combination of Reticulon-1C expression and anthracyclin treatment yielded more pronounced endoplasmic reticulum Ca2+ depletion than either of the two manipulations alone. Chelation of intracellular (and endoplasmic reticulum) Ca2+, targeted expression of the ligand-binding domain of the IP3 receptor and inhibition of the sarco-endoplasmic reticulum Ca2+-ATPase pump reduced endoplasmic reticulum Ca2+ load and promoted pre-apoptotic CRT exposure on the cell surface, in SH-SY5Y and HeLa cells. These results provide evidence that endoplasmic reticulum Ca2+ levels control the exposure of CRT.
Similar content being viewed by others
Main
In contrast to prior belief, apoptotic cell death can be immunogenic and hence elicits an active immune response against dying tumor cells.1 This is therapeutically relevant because immune defects that compromise the response against apoptotic cells reduce the efficacy of anticancer chemotherapy, both in suitable animal models and in patients.2 We found that anthracyclins and γ-irradiation are particularly efficient in inducing immunogenic cell death, at least in mouse models.3, 4, 5 The immunogenicity of cellular demise correlates with the exposure of calreticulin (CRT) on the plasma membrane (PM) surface of stressed tumor cells, a phenomenon that manifests before the cells acquire signs of apoptosis such as phosphatidylserine exposure. Inhibition of CRT exposure curtails the capacity of anthracyclin-treated or irradiated tumor cells to vaccinate against cancer and reduces the therapeutic efficacy of anthracyclins on tumors established in immunocompetent hosts.3, 4, 5 Provision of recombinant CRT or drug-mediated enforcement of CRT exposure rendered per se nonimmunogenic chemotherapies (for instance with etoposide and mitomycin C) immunogenic and boosted their therapeutic efficacy.5 These results suggest that CRT exposure is both necessary and sufficient to render conventional chemotherapies immunogenic.
CRT is an abundant Ca2+-binding chaperone that is mostly present in the endoplasmic reticulum (ER) lumen, although it can also be found in other subcellular localizations.6, 7 When present on the surface of damaged cells, it can serve as an ‘eat-me’ signal and hence facilitate the recognition and later engulfment of the dying cells by macrophages8 or by dendritic cells.5 It is thought that this function determines the immunostimulatory effect of CRT, because presentation of tumor antigens by dendritic cells is indeed required for the immunogenic effect of anthracyclin-treated cancer cells.1, 5, 9 Alternatively or in addition, CRT may bind antigenic peptides from the tumor and facilitate their efficient presentation to T cells.10
The exposure of CRT on the cell surface induced by anthracyclins has been found to involve the translocation of pre-synthetized CRT, through an active process that relies on the activity of the actin cytoskeleton.2 It occurs within minutes after addition of the anthracyclin and does not involve a general mixing of the ER membrane with the PM, as indicated by the fact that the ER transmembrane protein calcineurin (a close CRT homolog) is not found on the cell surface.5 This is at difference with the reported mixing of intracellular membranes from the Golgi apparatus with the PM, which occurs at late-stage apoptosis concomitant with membrane blebbing.11, 12
Importantly, it has been found that cytoplasts (that is cells lacking a nucleus) were still able to expose CRT on the cell surface when they were treated with anthracyclins.5 This result indicates that anthracyclins induce CRT exposure through a non-nuclear, cytoplasmic effect. Thus, the anthracyclin-stimulated CRT exposure is not mediated by a classical DNA damage response (which would involve the nucleus). Anthracyclins have been reported to exert a direct toxic effect on the PM,13 to stimulate ceramide synthesis,14 to induce the generation of reactive oxygen species,15, 16 and to affect intracellular Ca2+ homeostasis, mainly by reducing ER Ca2+ concentrations,17, 18 perhaps through a direct effect on ER proteins such as calsequestrin.19
Based on the aforementioned information, we decided to investigate the impact of ER Ca2+ homeostasis on the regulation of CRT exposure on the surface of anthracyclin-treated tumor cells. To this aim, we characterized a neuroblastoma cell line, demonstrating that it fails to expose CRT on the surface upon treatment with anthracyclins, yet recovers this capacity after expression of a tetracycline-inducible reticulon-1C (RTN-1C) transgene, correlating with a reduced ER Ca2+ level. In addition, we used an extensive repertoire of pharmacological and genetic manipulations of the ER Ca2+ influx and efflux to document that a reduction of ER Ca2+ concentrations can favor the translocation of CRT to the cell surface.
Results and Discussion
Establishment and characterization of human neuroblastoma cells expressing inducible RTN-1C
Reticulons (RTNs) are evolutionary conserved proteins that are differentially expressed in different cell types.20, 21, 22 RTNs localize primarily to the ER membrane and possess unique N-terminal parts and a common 200-amino-acid C-terminal domain containing two long hydrophobic sequences that were suggested to form Ca2+-permeable pores in the ER membrane.23, 24, 25 RTN-1C represents the smallest variant of the reticulon 1 gene26 and it is specifically expressed by neurons and cells of neuroendocrine tissue.27 In our study, we used the previously developed tetracycline-inducible SH-SY5YRTN-1C human neuroblastoma model23 consisting of a SH-SY5Y cell line stably expressing tetracycline-inducible RTN-1C (SH-SY5YRTN-1C) and a control cell line expressing the regulator vector alone (SH-SY5YTet12) (Figure 1a). After addition of doxycycline, a tetracycline derivative, SH-SY5YRTN-1C cells overexpress RTN-1C within hours, reaching a peak around 6 h that remains constant for several days (Figure 1b). While most of the RTN-1C is present on intracellular membranes (‘Endo-RTN-1C’) (Figure 1c), some of it can also be detected on the PM surface (‘Ecto-RTN-1C’) by immunofluorescence staining of nonpermeabilized cells, either by digital imaging (Figure 1d) or cytofluorometric detection (Figure 1e). We have previously observed that RTN-1C-overexpressing cells (that is SH-SY5YRTN-1C treated with doxycycline) are relatively resistant against DNA-damaging agents such as etoposide or cisplatin, as compared to controls (SH-SY5YTet12 or SH-SY5YRTN-1C cells cultured in tetracycline-free conditions).23 In contrast, we found that the overexpression of RTN-1C had no effect on the propensity of cells to expose phosphatidylserine and to lose viability (Figure 2a and b) or to activate caspase-3 (Figure 2c) after treatment with the anthracyclin mitoxanthrone (MITO).
RTN-1C facilitates CRT exposure in response to anthracyclin treatment
When MITO was added to doxycycline-treated SH-SY5YTet12, no increase in the expression of ecto-CRT could be detected. Thus, the level of ecto-CRT, as detectable by immunofluorescence staining and subsequent cytofluorometric analysis, did not increase in MITO-treated SH-SY5YTet12 cells (Figure 3a, top panels). In marked contrast, we found that SH-SY5YRTN-1C neuroblastoma cells cultured in the presence of MITO did manifest an increase in the ecto-CRT level, as detectable by flow cytometry as soon as 30 or 120 min after addition of MITO (Figure 3a, bottom panels). It should be noted that neither SH-SY5YTet12 nor SH-SY5YRTN-1C cells did manifest any signs of apoptosis at these time points (Figure 2a and b), meaning that the MITO-induced ecto-CRT exposure is an early event. MITO-triggered ecto-CRT exposure is a pre-apoptotic feature in the sense that it is found on cells that still lack phosphatidylserine exposure. Later, after 24 h of stimulation, MITO induced bona fide apoptosis, exactly as in mouse colon cancer and fibrosarcoma cells,1 as indicated by chromatin condensation (not shown) and caspase activation (Figure 2c). MITO did not induce an increase in total CRT levels, as determined by immunoblot analysis (Figure 3b), suggesting that ecto-CRT exposure is due to the redistribution rather than de novo synthesis of CRT. The increase in ecto-CRT on the surface of doxycycline-pretreated and MITO-treated SH-SY5YRTN-1C cells could also be detected by in situ immunofluorescence staining, revealing a patchy distribution of ecto-CRT, usually only in one single area of the PM (Figure 3c). While there was some background staining in control cells, we consistently found an increase in ecto-CRT when the overexpression of RTN-1C was combined with MITO treatment. Although ecto-CRT colocalized with ecto-RTN-1C in the same area of the cell surface (Figure 3d), we failed to co-immunoprecipitate CRT and RTN-1C either before or after MITO treatment (not shown). Accordingly, the subcellular localization of endo-CRT and endo-RTN-1C only partially overlapped, as determined by confocal imaging of permeabilized cells (Supplementary Figure 1). As an internal control, brefeldin A (BFA) fully blocked the ecto-CRT exposure induced by MITO in RTN-1C-overexpressing cells (Figure 4a), causing a perinuclear accumulation of endo-CRT and endo-RTN-1C (Figure 4b). This indicates that the anthracyclin-induced translocation of CRT from the ER to the cell surface is not due to passive leakage of the protein from the lumen of the ER, suggesting that it is plausibly an active process.
Altogether, these results indicate that RTN-1C can facilitate the active translocation of pre-formed CRT from the cytoplasm (endo-CRT) to the cell surface (ecto-CRT).
RTN-1C and MITO reduce ER luminal [Ca2+] in a concerted manner
In order to determine the effect of RTN-1C overexpression on ER Ca2+ homeostasis, SH-SY5YRTN-1C cells were infected with an adenoviral construct encoding ER-targeted low-affinity aequorin probe (ad-er-AEQ), and RTN-1C induction was achieved by the addition of doxycycline as detailed above (see Figure 1b).
The steady-state concentration of Ca2+ in the ER lumen ([Ca2+]ER) varies between 200 and 800 μM, depending on the cell type and the state of the cell, and is determined by the balance between Ca2+ accumulation into and Ca2+ release from the organelle. In the last decade, several methods have been developed for dynamic assessment of [Ca2+]ER in living cells.28 The aequorin-based measurement, applied in our study, is based on a protocol which includes (i) pre-incubation of cells with the aequorin cofactor coelenterazine n, following complete Ca2+ depletion of the ER in Ca2+-free medium; (ii) refilling of the ER by addition of 1 mM CaCl2 to the extracellular medium until [Ca2+] in the ER lumen ([Ca2+]ER) reaches steady state; and (iii) release of Ca2+ through Ca2+ leak or release channels29, 30 (see also Materials and Methods). The strategic advantage of this protocol was that it allowed us to analyze separately the three fundamental parameters of ER Ca2+ homeostasis, respectively: (i) Ca2+ accumulation into the ER, through the complex interplay between store-operated Ca2+ influx into the cell immediately followed by its transport into the ER lumen by sarcoendoplasmic reticulum Ca2+-ATPase (SERCA);31, 32 (ii) steady-state ER luminal Ca2+ concentration ([Ca2+]ER) determining Ca2+-dependent folding and redox processes of the organelle33, 34; and (iii) the Ca2+ leak observed after inhibition of SERCA-mediated Ca2+ uptake by 2,5-di(t-butyl)-1,4-benzohydroquinone (tBHQ)29 (Figure 5a). As shown on Figure 5a and b (top panel), RTN-1C overexpression led to partial reduction of the steady-state [Ca2+]ER. This effect is in line with our previous report on a reduced carbachol-releasable Ca2+ pool and elevated basal cytoplasmic Ca2+ levels in SH-SY5YRTN-1C cells.23 Moreover, our analysis revealed that the reduction of [Ca2+]ER was, for the most part, the consequence of the significant inhibition of Ca2+ accumulation into the ER, following Ca2+ addition to the extracellular space (Figure 5b, middle panel). Even if the mean Ca2+ leak was increased, it did not reach a statistically significant level (Figure 5b, lower panel). Transient transfection of HeLa cells with RTN-1C also led to reduction of [Ca2+]ER (Supplementary Figure 2).
Since RTN-1C facilitates CRT exposure in response to anthracyclin treatment (see Figure 3a and c), we decided to analyze the combined effect of MITO and RTN-1C overexpression on the above parameters of ER Ca2+ handling. MITO also reduced [Ca2+]ER, both in RTN-1C-overexpressing and in control cells (that is SH-SY5YRTN-1C cells cultured in the presence or absence of doxycycline, respectively, Figure 5b, top panel). This effect of MITO involved (i) a major inhibition of the Ca2+ accumulation from the extracellular space into the ER lumen (Figure 5b middle panel), but (ii) also rendered the ER more leaky to Ca2+, resulting in significant increase of Ca2+ loss following tBHQ addition (Figure 5b, lower panel). Altogether, the combination of RTN-1C overexpression and MITO treatment was particularly efficient in depleting [Ca2+]ER levels, by combining a reduced Ca2+ accumulation and an enhanced Ca2+ efflux.
Reduction of ER Ca2+ load triggers CRT exposure
As shown above, RTN-1C and MITO both reduce [Ca2+]ER levels and induce ecto-CRT. To causally link both phenomena, we sought to reduce [Ca2+]ER by different techniques and to monitor the effect of these manipulations on CRT exposure. For this set of experiments, we utilized HeLa cells, allowing pharmacological treatment and transient overexpression of constructs interacting with the ER Ca2+ handling apparatus in the same cellular model. Thus, we applied MITO (Figure 6a), the intracellular Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetracetate acetyloxy methylester (BAPTA-AM) (Figure 6b), and the expression of an ER-targeted IP3 receptor ligand-binding domain (LBD) construct (ER-targeted IP3 receptor ligand binding domain (ER-IP3R-LBD)224–605) that is known to reduce [Ca2+]ER in HeLa cells35, 36 (Figure 6c). A significant depletion of the ER Ca2+ pool was observed in all cases, as reflected by the reduced steady-state [Ca2+]ER values (Figure 6a–c upper panels). Interestingly, the tendency was similar to the effect of RTN-1C, that is, the steady-state [Ca2+]ER was unbalanced by reduced ER filling (see Figure 6a–c middle panels). Next, we analyzed the effect of the aforementioned strategies on CRT exposure on the cell surface. Importantly, all manipulations induced some degree of CRT exposure (Control<MITO<BAPTA-AM<ER-IP3R-LBD224–605, Figure 6d and e). Moreover, these data were confirmed in the neuroblastoma cell model. In doxycycline-treated SH-SY5YRTN-1C (RTN-1C overexpressing) cells, the chelation of Ca2+ with BAPTA-AM strongly enhanced the MITO-induced CRT exposure with respect to SH-SY5YTet12 (control) cells (Figure 7). Based on these data, we concluded that Ca2+ is a major regulator of CRT translocation. In particular, it appears that the reduction of Ca2+ refilling into the ER from the extracellular space serves as a trigger for CRT translocation. It is important to note that none of these manipulations induced apoptosis within the time frame that was analyzed (2 h for MITO, BAPTA-AM, 24 h post-transfection for ER-IP3R-LBD224–605), underscoring that CRT exposure is not directly linked to cell death.
The refilling of the ER after Ca2+ depletion was recently explained in mechanistic terms by the interaction of Ca2+ sensors residing in the ER membrane and store-operated Ca2+ channels of the PM (e.g. the Orai family of Ca2+ channels).37, 38 ER Ca2+ depletion triggers activation of Ca2+ influx through the PM, which is immediately taken up by the ER through the SERCA pumps.32 To determine whether reduced ER refilling of RTN-1C-overexpressing cells reflects inhibition of Ca2+ influx through the PM, or inhibition of active transport into the ER lumen by the SERCA pumps, we applied two different approaches.
First, we measured the kinetics of Ca2+ uptake into the ER in cells in which the PM was permeabilized by a low dose of digitonin. Increasing the concentration of ATP (from 100 to 400 μM) in the incubating medium augmented SERCA activity, as it was reflected by the increased Ca2+ filling rate of the ER. The overexpression of RTN-1C had no significant effect on SERCA activity (Figure 8a). These results suggest that putative interactions between RTN-1C and SERCA cannot account for the RTN-1C-facilitated CRT exposure. Next, in order to directly assess the effect of RTN-1C on Ca2+ influx through the PM, we measured the kinetics of the increase of cytosolic [Ca2+] ([Ca2+]c) after induction of capacitative Ca2+ influx by ER Ca2+ depletion (Figure 8b). SH-SY5YRTN-1C cells with (RTN-1C overexpressing) or without (controls) doxycycline treatment were first perfused with Ca2+-free Krebs Ringer-modified Buffer (KRB) containing 100 μM EGTA and then treated for 5 min with 50 μM tBHQ to deplete ER Ca2+ content. At last, Ca2+ influx was induced by the addition of 1 mM CaCl2 to the KRB buffer while removing EGTA (Figure 8b, left panel). Importantly, RTN-1C overexpression significantly reduced the Ca2+ influx rate (Figure 8b, right panel), unraveling the molecular target by which the protein exerts its effect on Ca2+ refilling of the ER.
In conclusion, we deciphered the complex mechanism by which RTN-1C modifies ER and cellular Ca2+ homeostasis. This mechanism includes actions both on the ER and the PM, in agreement with the double localization of the protein. Indeed, RTN-1C appears to increase Ca2+ leak from the ER lumen to the cytosol, accounting for elevated basal [Ca2+]c as they were observed in doxycycline-treated SH-SY5YRTN-1C cells.23 In addition, RTN-1C also inhibits capacitative Ca2+ influx at the PM level, further reducing the steady-state [Ca2+] in the ER. Similarly, the effect of RTN-1C on CRT cell surface exposure cannot be accounted for by an effect on a single target. Thus, even though the reduction of ER Ca2+ refilling by RTN-1C was mediated by the inhibition of PM Ca2+ channels, inhibition of the SERCA pump by thapsigargin was also able to induce CRT exposure, and this effect was more evident in SH-SY5YRTN-1C cells following RTN-1C induction (Figure 8c). This suggests that any manipulation leading to [Ca2+]ER depletion may stimulate CRT exposure, irrespective of the exact mechanism by which this depletion is achieved. Further experiments are needed to clarify the exact role of the individual components of ER Ca2+ homeostasis in generating the signal for triggering CRT exposure onto the cellular surface. Whether cell surface CRT itself modifies Ca2+ fluxes cannot be excluded, yet appears improbable because this protein has thus far been viewed as a mere Ca2+ buffer. Indeed, induction of CRT exposure with inhibitors of protein phosphatase 1 (PP1) failed to cause significant changes in [Ca2+]ER (not shown), underscoring that ecto-CRT by itself does not modulate Ca2+ fluxes.
Concluding Remarks
Based on the data summarized in this work, we assume that ER Ca2+ homeostasis plays a major role in the regulation of CRT exposure as it is induced by anthracyclins. Our data corroborate that anthracyclins can reduce the ER Ca2+ concentration.17, 18, 19 Although statistically significant and consistent (in more than 15 independent experiments), this effect is far from spectacular, at least in SH-SY5Y neuroblastoma cells. Upon RTN-1C overexpression (which reduces ER Ca2+ influx and hence further lowers the [Ca2+]ER) or after treatment with the Ca2+ chelator BAPTA-AM (which also reduces ER Ca2+ influx), however, SH-SY5Y cells acquired the capacity to expose CRT in response to anthracyclins. These results suggest that threshold effects operating at the level of [Ca2+]ER may determine the propensity of different cell types to translocate CRT to the cell surface. As a further indication that [Ca2+]ER controls CRT exposure, we observed that two further specific manipulations designed to lower [Ca2+]ER could stimulate the appearance of CRT on the cell surface: inhibition of SERCA pumps with thapsigargin and transfection with ER-IP3R-LBD224–605.
Although the before mentioned results clearly demonstrate that [Ca2+]ER controls CRT exposure, several problems remain to be resolved. First, it is not clear whether a reduction of [Ca2+]ER levels is the sole mediator responsible for CRT exposure induced by an array of different stressors or whether alternative routes to stress-induced CRT exposure may exist. To answer this question, it will be necessary to screen an array of chemical or physical stressors for their effects on CRT exposure and [Ca2+]ER levels. Second, the kinetics of CRT exposure and apoptosis induction proceeds at rather different paces. While CRT exposure elicited by anthracyclins is a rapid phenomenon (that manifests within minutes or few hours), apoptosis occurs much later (within >12 h), raising questions on the functional relationship between the two phenomena. Indeed, transfection with ER-IP3R-LBD224–605 can stimulate CRT exposure. However, this manipulation does not trigger an apoptotic response, suggesting that CRT exposure and apoptosis induction can be uncoupled. Third, at present it remains unknown which pool of CRT translocates to the surface. Immunofluorescence experiments performed on permeabilized versus nonpermeabilized cells did not reveal a net reduction of intracellular CRT that would accompany the exposure of CRT on the surface. Thus, there is only a fraction of CRT that may translocate to the cell surface. The subcellular origin and the biochemical features of this ecto-CRT pool have to be determined. Fourth, the experiments shown here have been performed on human neuroblastoma and cervical cancer cells, which are not suitable for determining the immunological consequences of [Ca2+]ER-regulated CRT exposure. Thus, future studies performed on RTN-1C-expressing mouse tumor cells will have to confirm their enhanced CRT-dependent immunogenicity after in vivo treatment with anthracyclins.
We have recently reported that CRT exposure could be observed in a fraction of circulating leukemia cells from patients treated by intravenous injection with anthracyclins.39 However, CRT exposure could not be found in all leukemias, pointing to a hitherto unsuspected heterogeneity in the mechanisms of CRT exposure. The mechanisms accounting for this deficient CRT exposure remain largely elusive, although they may be related to altered ER Ca2+ homeostasis. It is tempting to speculate that tumors that fail to expose CRT would be refractory to the immunological component of chemotherapy and hence would demonstrate a poorer prognosis than tumors that conserve an intact CRT translocation response. This possibility is currently under intense investigation in our laboratory.
Materials and Methods
Antibodies and reagents
The rabbit polyclonal (FMC 75) to calreticulin (ab2907) and the mouse monoclonal (RNL-4) to NSP-A+NSP-B (ab8961) antibodies were from Abcam. The mouse anti-actin monoclonal antibody was from AbCys S.A. The rabbit anticleaved caspase 3 was from Cell Signaling. Ionomycin, EGTA, bovine serum albumin (BSA), digitonin, CaCl2 were from Sigma Aldrich. Mitoxanthrone, BFA, BAPTA-AM, thapsigargin were obtained by Calbiochem. Doxycycline was purchased by Clontech. Lipofectamineâ„¢ 2000 reagent, blasticidin S HCl and zeocinâ„¢ were from Invitrogen.
RTN-1C expression plasmid
The full length of human RTN-1C cDNA was subcloned into the Invitrogen (Carlsbad, CA, USA) pcDNA3.1/Zeo vector to generate the pcDNA 3.1/Zeo RTN-1C plasmid and confirmed by sequencing.
Cells, transfection, treatments
The stably transfected clones for RTN-1C sense were obtained as previously described.23 The SH-SY5Y human neuroblastoma cell line and the derived clones were grown in 1 : 1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 with Glutamax (GIBCO, Invitrogen) supplemented with 10% tetracycline-free heat-inactivated fetal bovine serum (FBS, Clontech) in a humidified atmosphere of 5% CO2 in air under selective conditions by adding blasticidin and zeocin periodically. HeLa cells were maintained in DMEM supplemented with 10% heat-inactivated FBS, 10 mM Hepes, 100 U/ml penicillin, and 100 μg/ml streptomycin. For transfection of HeLa cells, 1 × 105 cells/well were seeded into 12-well plates and transfected 24 h later with each expression vector plasmid by using lipofectamine™ 2000 according to the manufacturer's instructions. All experiments in SH-SY5YRTN-1C were performed on cells after 12 h of induction by doxycycline (2 μg/μl).
Assessment of apoptosis
Redistribution of PM phosphatidylserine is a marker of apoptosis and was assessed by annexin fluorescein isothiocyanate (MACS, Miltenyi Biotech) according to the manufacturer's protocol. Briefly, 2 × 105 cells per sample were collected, washed in phosphate-buffered saline (PBS), pelleted, and resuspended in incubation buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl2) containing 1% annexin V. Samples were kept in the dark and incubated for 15 min prior to addition of another 400 μl of incubation buffer and subsequent analysis on a fluorescence-activated cell sorter Calibur flow cytometer (Becton Dickinson) using Cell Quest software.
Flow cytometric analysis of CRT and RTN-1C on the cell surface
Flow cytometry was used to detect CRT and RTN-1C exposure induced by different drugs. Briefly, 2 × 105 cells were plated in 12-well plates and the day after treated with different drugs for 2 h. Cells were harvested, washed twice with PBS and fixed in 0.25% paraformaldehyde (PFA) in PBS for 5 min. After washing again twice in cold PBS, cells were incubated for 30 min with primary antibody, diluted in cold blocking buffer (2% FBS in PBS), followed by washing and incubation with the FITC-conjugated monoclonal or polyclonal secondary antibody diluted 1:500 in blocking buffer (30 min). Each sample was then analyzed by FACScan (Becton Dickinson) to identify cell-surface CRT and RTN-1C. Isotype-matched IgG antibodies were used as a control, and the fluorescent intensity of stained cells was gated on propidium iodide (PI) or 4′,6-diamidino-2-phenylindole (DAPI)-negative cells. Data were recorded on a logarithmic scale and analyzed using Cell Quest software. Results are shown both as frequency histograms and, after quantification of mean fluorescence intensity values, also as fold induction in bar charts.
Immunofluorescence
For surface staining: cells were cultured on 13 mm-round glass coverslips as described above. After treatment, cells were placed on ice, washed twice with PBS and fixed in 0.25% PFA in PBS for 5 min. Cells were then washed twice in PBS and primary antibody, diluted in cold blocking buffer, was added for 30 min. After three washes in cold PBS, cells were incubated for 30 min with the appropriate secondary antibody diluted 1:500 in cold blocking buffer. Cells were washed with PBS and mounted on slides with the mounting medium including DAPI from Vectashield. For intracellular staining: cells were washed with PBS, fixed with 4% PFA for 15 min, permeabilized with 0.1% Triton X-100 for 10 min, rinsed three times with PBS, and nonspecific binding sites were blocked with 10% FBS in PBS for 30 min. Primary antibody was added for 1 h. Subsequently, cells were washed three times with PBS and incubated for 30 min in Alexa Fluor FITC or TRITC-conjugated secondary antibodies (1:1000, Molecular Probes). Specimens were imaged by a brightfield microscope coupled to a cooled CCD camera or a Zeiss LSM 510 confocal system.
Western blot analyses
Cells were harvested and homogenized in RIPA lysis buffer (10 mM Tris, pH 7.2, 150 mM NaCl, 1% deoxycholate, 1% Triton, 0.1% SDS, 5 mM EDTA) containing complete protease inhibitor cocktail (Roche Diagnostics, Meylan, France). After 1 h on ice, samples were sonicated and protein quantification was carried out using a Bio-Rad protein assay. Equal amounts of soluble proteins (15–25 μg) were denaturated by boiling and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. After blocking in 5% non-fat dry milk in PBS for 1 h and probing with a specific primary antibody and a horseradish peroxidase-conjugated secondary antibody, the protein bands were detected by chemiluminescence (Supersignal, Pierce) and X-ray film exposure (Kodak). Protein loading was normalized by using anti-tubulin or anti-actin antibodies.
Dynamic in vivo [Ca2+] measurements
For [Ca2+]ER measurements, HeLa cells were cotransfected with pcDNA1-er-AEQ and the appropriate cDNAs, or SH-SY5YRTN-1C cells were infected with an ad-er-AEQ adenoviral construct (kind gift of M Chami, INSERM U807, Paris). Cells were reconstituted with coelenterazine n, following ER Ca2+ depletion in a solution containing 0 [Ca2+], 600 μM EGTA, 1 μM ionomycin, for 1 h at 4°C, as previously described.35 Following reconstitution, cells were washed with KRB (Krebs–Ringer modified buffer: 135 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.4 mM K2HPO4, 5.5 mM glucose, 20 mM HEPES, pH=7.4) containing 1 mM EGTA and 2% BSA, and transferred to the perfusion chamber. Light signal was collected in a purpose-built luminometer and calibrated into [Ca2+] values as previously described.29 Ca2+ reuptake into ER was initiated by the addition of KRB containing 1 mM CaCl2. Measurement of Ca2+ uptake into the ER in permeabilized cells was performed in a similar way except that, after the BSA washing step, cells were perfused with an intracellular-like solution containing 25 μM digitonin as previously described.40 [Ca2+] was kept controlled by the use of 2 mM EGTA and 2 mM HEDTA and free ionic concentrations were calculated with the Max-Chelator software.41 [Mg2+] was kept constant at 2 mM while [ATP] varied between 100 and 400 μM. Ca2+ uptake was initiated by the addition of 200 nM free [Ca2+]. Cytosolic [Ca2+] measurements were performed on cells infected with an adenoviral ad-cyt-AEQ vector as previously described.29
Statistical analyses
Statistical analyses were performed using the Student's t-test. A P-value of 0.05 was considered as significant. All data are reported as means±S.E.M.
Abbreviations
- BAPTA-AM:
-
1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetracetate acetyloxy methylester
- BFA:
-
brefeldin A
- BSA:
-
bovine serum albumin
- CRT:
-
calreticulin
- DAPI:
-
4′,6-diamidino-2-phenylindole
- DMEM:
-
Dulbecco's modified Eagle's medium
- ER:
-
endoplasmic reticulum
- ER-IP3R-LBD:
-
ER-targeted IP3 receptor ligand binding domain
- FBS:
-
fetal bovine serum
- KRB:
-
Krebs Ringer-modified Buffer
- mRFP:
-
monomeric Red Fluorescent Protein
- PBS:
-
phosphate-buffered Saline
- PFA:
-
paraformaldehyde
- PI:
-
propidium iodide
- PM:
-
plasma membrane
- PP1:
-
protein phosphatase 1
- RTN:
-
Reticulon
- SERCA:
-
sarcoendoplasmic reticulum Ca2+-ATPase
References
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691–1701.
Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G . Immune response against dying tumor cells. Adv Immunol 2004; 84: 131–179.
Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007; 220: 22–34.
Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14: 1848–1850.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54–61.
Johnson S, Michalak M, Opas M, Eggleton P . The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol 2001; 11: 122–129.
Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M . Calreticulin: one protein, one gene, many functions. Biochem J 1999; 344 (Part 2): 281–292.
Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123: 321–334.
Apetoh L, Ghriringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anti-cancer chemo- and radiotherapy. Nat Med 2007; 4: 65–70.
Srivastava PK . Heat shock protein-based novel immunotherapies. Drug News Perspect 2000; 13: 517–522.
Franz S, Herrmann K, Fuhrnrohr B, Sheriff A, Frey B, Gaipl US et al. After shrinkage apoptotic cells expose internal membrane-derived epitopes on their plasma membranes. Cell Death Differ 2007; 14: 733–742.
Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99–163.
Maestre N, Tritton TR, Laurent G, Jaffrezou JP . Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. Cancer Res 2001; 61: 2558–2561.
Delpy E, Hatem SN, Andrieu N, de Vaumas C, Henaff M, Rucker-Martin C et al. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res 1999; 43: 398–407.
Laurent G, Jaffrezo JP . Signaling pathways activated by daunorubicin. Blood 2001; 98: 913–924.
Ravi D, Muniyappa H, Das KC . Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 2005; 280: 40084–40096.
Kim DH, Landry AB, Lee YS, Katz AM . Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 1989; 21: 433–436.
Takahashi S, Denvir MA, Harder L, Miller DJ, Cobbe SM, Kawakami M et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in ‘chemically-skinned’ rabbit ventricular trabeculae. Jpn J Pharmacol 1998; 76: 405–413.
Kim E, Tam M, Siems WF, Kang C . Effects of drugs with muscle-related side effects and affinity for calsequestrin on the calcium regulatory function of sarcoplasmic reticulum microsomes. Mol Pharmacol 2005; 68: 1708–1715.
Roebroek AJ, Contreras B, Pauli IG, Van de Ven WJ . cDNA cloning, genomic organization, and expression of the human RTN2 gene, a member of a gene family encoding reticulons. Genomics 1998; 51: 98–106.
Grand T, Nakamura F, Vartanian T, Strittmatter SM . Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature 2000; 403: 439–444.
Moreira EF, Jaworski CJ, Rodriguez IR . Cloning of a novel member of the reticulon gene family (RTN3): gene structure and chromosomal localization to 11q13. Genomics 1999; 58: 73–81.
Di Sano F, Fazi B, Tufi R, Nardacci R, Piacentini M . Reticulon-1C acts as a molecular switch between endoplasmic reticulum stress and genotoxic cell death pathway in human neuroblastoma cells. J Neurochem 2007; 102: 345–353.
Oertle T, Schwab ME . Nogo and its paRTNers. Trends Cell Biol 2003; 13: 187–194.
van de Velde HJ, Roebroek AJ, Senden NH, Ramaekers FC, Van de Ven WJ . NSP-encoded reticulons, neuroendocrine proteins of a novel gene family associated with membranes of the endoplasmic reticulum. J Cell Sci 1994; 107: 2403–2416.
Roebroek AJ, Ayoubi TA, Van de Velde HJ, Schoenmakers EF, Pauli IG, Van de Ven WJ . Genomic organization of the human NSP gene, prototype of a novel gene family encoding reticulons. Genomics 1996; 32: 191–199.
Hens J, Nuydens R, Geerts H, Senden NH, Van de Ven WJ, Roebroek AJ et al. Neuronal differentiation is accompanied by NSP-C expression. Cell Tissue Res 1998; 292: 229–237.
Demaurex N . Calcium measurements in organelles with Ca2+-sensitive fluorescent proteins. Cell Calcium 2005; 38: 213–222.
Chiesa A, Rapizzi E, Tosello V, Pinton P, de Virgilio M, Fogarty KE et al. Recombinant aequorin and green fluorescent protein as valuable tools in the study of cell signalling. Biochem J 2001; 355: 1–12.
Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R . The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J 2001; 20: 2690–2701.
Parekh AB, Putney Jr JW . Store-operated calcium channels. Physiol Rev 2005; 85: 757–810.
Jousset H, Frieden M, Demaurex N . STIM1 knockdown reveals that store-operated Ca2+ channels located close to sarco/endoplasmic Ca2+ ATPases (SERCA) pumps silently refill the endoplasmic reticulum. J Biol Chem 2007; 282: 11456–11464.
Michalak M, Robert Parker JM, Opas M . Ca2+ signaling and calcium binding chaperones of the endoplasmic reticulum. Cell Calcium 2002; 32: 269–278.
Williams DB . Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 2006; 119: 615–623.
Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR, Cavagna D et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol 2006; 175: 901–911.
Varnai P, Balla A, Hunyady L, Balla T . Targeted expression of the inositol 1,4,5-triphosphate receptor (IP3R) ligand-binding domain releases Ca2+ via endogenous IP3R channels. Proc Natl Acad Sci USA 2005; 102: 7859–7864.
Smyth JT, Dehaven WI, Jones BF, Mercer JC, Trebak M, Vazquez G et al. Emerging perspectives in store-operated Ca2+ entry: roles of Orai, Stim and TRP. Biochim Biophys Acta 2006; 1763: 1147–1160.
Soboloff J, Spassova MA, Dziadek MA, Gill DL . Calcium signals mediated by STIM and Orai proteins – a new paradigm in inter-organelle communication. Biochim Biophys Acta 2006; 1763: 1161–1168.
Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med 2007; 85: 1069–1076.
Rapizzi E, Pinton P, Szabadkai G, Wieckowski MR, Vandecasteele G, Baird G et al. Recombinant expression of the voltage-dependent anion channel enhances the transfer of Ca2+ microdomains to mitochondria. J Cell Biol 2002; 159: 613–624.
Patton C, Thompson S, Epel D . Some precautions in using chelators to buffer metals in biological solutions. Cell Calcium 2004; 35: 427–431.
Acknowledgements
We thank A Jalil for his help in confocal microscopy experiments. This work has been supported by grants from the Ligue Nationale contre le Cancer (équipe labelliseé), Institut National du Cancer (INCa), Cancéropôle Ile-de-France, the European Union (ChemoRes), ARC (Association pour la Recherche contre le Cancer), INSERM (Institut National de Recherche et Santè Medicale), and a University College London startup grant to GS.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by P Krammer
The authors declare no competing financial interests.
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Rights and permissions
About this article
Cite this article
Tufi, R., Panaretakis, T., Bianchi, K. et al. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 15, 274–282 (2008). https://doi.org/10.1038/sj.cdd.4402275
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4402275
Keywords
This article is cited by
-
Calreticulin as a marker and therapeutic target for cancer
Clinical and Experimental Medicine (2022)
-
Connecting Calcium-Based Nanomaterials and Cancer: From Diagnosis to Therapy
Nano-Micro Letters (2022)
-
The Regulatory Role of Reticulons in Neurodegeneration: Insights Underpinning Therapeutic Potential for Neurodegenerative Diseases
Cellular and Molecular Neurobiology (2021)
-
Polyphenol-rich extract induces apoptosis with immunogenic markers in melanoma cells through the ER stress-associated kinase PERK
Cell Death Discovery (2019)
-
Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma
Genes & Immunity (2019)